PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Tulane University Medical Center, New Orleans, LA, USA.\', \'University Medical Center New Orleans, New Orleans, LA, USA.\', \'Chimerix, Inc, Durham, NC, USA. mmorrison@chimerix.com.\', \'Chimerix, Inc, Durham, NC, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s12325-020-01539-z
?:doi
?:hasPublicationType
?:journal
  • Advances in therapy
is ?:pmid of
?:pmid
?:pmid
  • 33108622
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.075
?:rankingScore_hIndex
  • 51
is ?:relation_isRelatedTo_publication of
?:title
  • Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33108622>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33108622>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all